•  
  •  

vaxeal emblem proposal final 72px

Science

Our state-of-the-art combined strategies overcome the limitations of traditional vaccine therapies.

 

vaxeal emblem proposal final 72px

Pipeline

Vaxeal aggregates the expertise of leading research centers producing an exceptional product pipeline.

vaxeal emblem proposal final 72px

Team

Vaxeal’s team has forged unique academic and industrial partnerships to reduce vaccine development time.

vaxeal emblem proposal final 72px

Growth

Vaxeal is targeting disease segments where high value markets are experiencing rapid growth.

We develop therapeutic vaccines to meet the growing need for improved anti-cancer treatments

Our unique and innovative scientific research, and our improved understanding of immunological mechanisms, is at the heart of Vaxeal’s mission to deliver cutting-edge therapies. Our vaccines address a wide spectrum of tumors aiming to improve long-term survival with limited adverse effects.

 

 
 

Patient quality of life

Vaxeal strives to promote quality of life for cancer patients by developing breakthrough therapeutic vaccines. The strategy resides in the restoration of appropriate immune responses in these patients using an innovative combined vaccine strategy thus overcoming the limitations to current vaccine approaches.

 

Predictive assays

Vaxeal is conducting extensive pre-clinical studies with human cells, from healthy donors and cancer patients, and in transplantable and spontaneous animal tumor models to predict the immunogenicity and therapeutic efficacy of the tumor vaccines developed in humans.

Extensive research

Vaxeal’s clinical portfolio is the result of 15 years of research and is unique in the biopharmaceutical sector. It is protected by numerous patents and is at the heart of Vaxeal’s anti-cancer therapeutic vaccines platforms. Each product developed at Vaxeal addresses major unmet medical needs.

 

  Strategic partnerships

Vaxeal has established long-term strategic partnerships with leading oncology research and clinical centers in order to optimize its R&D capabilities in order to access to the most advanced technologies, as well as state of the art knowledge.

Releases

Latest News

Vaxeal CEO Appointed Board Member of Vaccines Europe. Read more
pdf_iconDownload

Vaxeal Research receives a grant from the French National Research Agency. Read more
pdf_iconDownlaod

Ahmed Bouzidi, presented at the Stakeholder Workshop for SMEs organized by the IMI: Read more
pdf_iconDownload

Publications

vaxeal_snapshot_iconClick the icon to download the Vaxeal Executive Snapshot highlighting our unique and innovative scientific research, and our improved understanding of immunological mechanisms, which is at the heart of our mission to deliver cutting-edge therapies.

Vaxeal Offices

Vaxeal Holding SA
Avenue Paul Cérésole 24, 1800 Vevey – Switzerland
Phone: +41 21 977 3000 | Fax: +41 21 922 1000

Vaxeal Research SAS
Genopoles Entreprises, 4 Rue Pierre Fontaine, 91058 Evry Cedex – France
Phone: +33 1 60 87 89 31 | Fax: +33 1 60 87 89 99

Vaxeal IP Management Sàrl
Avenue de Tivoli 3, 1700 Fribourg – Switzerland

Vaxeal China Inc.
BioBay, 218 Xing Hu Road, A2 Building, Suite 214,
Suzhou Industrial Park, Suzhou 215125 – China

For any further information regarding Vaxeal products and solutions, please contact us at info@vaxeal.net

Follow us

Social media presence coming soon.

Dedicated to improving quality of life for cancer patients